Expanded Access Program of Ponatinib

Summary

This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications